Nortriptyline Dosing, Contraindications, and Monitoring
For adults, start nortriptyline at 10-25 mg nightly and titrate every 3-7 days to a target of 50-150 mg nightly, with therapeutic plasma levels maintained between 50-150 ng/mL. 1, 2
Dosing Guidelines
Standard Adult Dosing
- Starting dose: 10-25 mg at bedtime 1
- Titration schedule: Increase by 25 mg every 3-7 days as tolerated 3, 2
- Target dose: 50-150 mg nightly 1
- Maximum dose: 150 mg/day (doses above this are not recommended) 2
- Alternative regimen: Total daily dose may be given once daily 2
The guideline evidence consistently emphasizes that nortriptyline is better tolerated than tertiary amine tricyclics (amitriptyline, imipramine) due to fewer anticholinergic effects, though it may be slightly less efficacious 1.
Elderly Patients
- Starting dose: 10 mg at bedtime 4
- Target dose: 30-50 mg/day in divided doses 2
- Maximum dose: 40 mg per day (given twice daily) 4
- Therapeutic window: 50-150 ng/mL plasma level 4
Critical caveat: Elderly patients are at higher risk for toxic plasma concentrations and may develop elevated levels of the active metabolite 10-hydroxynortriptyline, which can cause cardiotoxicity even when nortriptyline levels appear therapeutic 2. Use approximately 50% of standard adult starting doses 5.
Therapeutic Drug Monitoring
Plasma level monitoring is essential for optimal dosing. 2, 6
- Therapeutic range: 50-150 ng/mL 3, 2, 6
- When to monitor: When doses exceed 100 mg daily 2
- Response correlation: A therapeutic window exists—levels between 50-139 ng/mL show better response than levels of 140-260 ng/mL 6
Recent research demonstrates that both pharmacogenetics-based and phenotype-based dosing (using plasma concentration after a single dose) significantly improve the likelihood of achieving therapeutic levels compared to standard dosing 7. A single 50 mg dose with plasma measurement at 24 hours can predict the required maintenance dose 8.
Contraindications and Precautions
Absolute Contraindications (from FDA label)
- Acute recovery phase post-myocardial infarction 2
- Concurrent use with MAO inhibitors (implied by drug class)
- Hypersensitivity to nortriptyline 2
Major Cardiovascular Concerns
Nortriptyline produces sinus tachycardia and prolongs cardiac conduction time. 2 Myocardial infarction, arrhythmias, and strokes have occurred with use. Patients with cardiovascular disease require close supervision 2.
High-Risk Populations Requiring Caution
- Glaucoma or urinary retention history: Due to anticholinergic activity 2
- Seizure history: Lowers convulsive threshold; close monitoring required 2
- Hyperthyroid patients or those on thyroid medication: Risk of cardiac arrhythmias 2
- Bipolar disorder risk: Screen all patients before initiating—may precipitate manic episodes 2
- Hepatic or renal disease: Dose reduction may be necessary 5, 2
Black Box Warning: Suicidality
All patients on antidepressants require close monitoring for suicidality, especially during initial months and dose changes. 2 Risk is highest in patients under age 25 (14 additional cases per 1000 treated vs. placebo), while patients over 65 show decreased risk (6 fewer cases per 1000) 2.
Monitoring Recommendations
Clinical Monitoring
- Initial phase: Monitor closely for clinical worsening, suicidality, and unusual behavioral changes, particularly in the first few months 2
- Symptoms requiring immediate attention: Anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, hypomania, mania 2
- Cardiovascular: Monitor for tachycardia, arrhythmias, blood pressure changes 2
- Anticholinergic effects: Assess for sedation, dry mouth, urinary hesitancy 1
Laboratory Monitoring
- Plasma nortriptyline levels: Mandatory when doses exceed 100 mg/day; target 50-150 ng/mL 2
- Consider baseline ECG in patients with cardiovascular risk factors (not explicitly stated in guidelines but clinically prudent given cardiac risks)
- Hepatic function: Monitor if hepatic disease present 5
Duration of Treatment
Continue treatment for 4-12 months after first depressive episode. 5 Patients with recurrent depression may require prolonged treatment. After 9 months, consider dose reduction to reassess need for continued medication 4.
Special Considerations
Drug Interactions
- Alcohol: Potentiating effect increases risk of suicidal attempts and overdosage 2
- Guanethidine: Antihypertensive action may be blocked 2
- CYP2D6 substrates/inhibitors: Nortriptyline exhibits nonlinear kinetics related to CYP2D6 metabolism 9; dose-dependent kinetics occur in intermediate and extensive metabolizers 9
Pregnancy and Lactation
Safety not established. Use only when potential benefits outweigh possible hazards 2. Animal studies yielded inconclusive results 2.
Analgesic Use (Neuropathic Pain)
When used as a coanalgesic for neuropathic pain, analgesic effectiveness is independent of antidepressant activity, with lower doses often effective and earlier onset of action 1. Frequently combined with opioids for neuropathic pain components 1.
Practical Prescribing
- Prescribe smallest quantity consistent with good management to reduce overdose risk 2
- Warn patients about impaired mental/physical abilities for operating machinery or driving 2
- Educate about trial-and-error nature of treatment to prevent discouragement 1
- Titrate until analgesic effect achieved, side effects become unmanageable, or maximum dose reached 1